Current drugs and future hopes in the treatment of Alzheimer's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 62, 2002, Pages 149-164

  Windisch, M ^a   Hutter Paier, B ^a   Schreiner, E ^a  

^a JSW Life Sciences GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; BETA CAROTENE; BETA SECRETASE; BIOLOGICAL MARKER; BM 15 766; CEREBROLYSIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; ENZYME INHIBITOR; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LETEPRINIM; MEMANTINE; MEVINOLIN; MONOAMINE OXIDASE B INHIBITOR; MUSCARINIC M1 RECEPTOR AGONIST; RIVASTIGMINE; SIMVASTATIN; TACRINE; UNCLASSIFIED DRUG; NERVE GROWTH FACTOR;

ALZHEIMER DISEASE; BETA SHEET; CHOLINERGIC TRANSMISSION; CONFERENCE PAPER; DISEASE COURSE; DRUG TOLERABILITY; HUMAN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROMODULATION; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; VACCINATION; AGED; PATHOLOGY; REVIEW;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; NERVE GROWTH FACTORS;

EID: 0036044614     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6139-5_15     Document Type: Conference Paper

References (102)

1. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 7: 213-221
2. Amenta F, Parnetti L, Gallai V, Wallin A (2001) Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Age Dev 122: 2025-2040
3. Anand R, Gharabawi G (1996) Clinical development of ExelonTM (ENA-713): the Adena programme. J Drug Dev Clin Pract 8: 117-122
4. Arendt T, Brückner MK, Pagliusi S, Krell T (1995) Degeneration of rat cholinergic basal forebrain neurons and reactive changes in nerve growth factor expression after chronic neurotoxic injury. I. Degeneration and plastic response of basal forebrain neurons. Neuroscience 65: 633-645
5. Avery EE, Baker LD, Asthana S (1997) Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging 11: 450-459
6. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163: 495-529
7. Bayer TA, Wirths O, Majtényi K, Hartmann T, Multhaup G, Beyreuther K, Czech C (2001) Key factors in Alzheimer's disease: β-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 11: 1-11
8. Burn DJ, Jaros E (2001) Multiple system atrophy: cellular and molecular pathology. Mol Pathol 54: 419-426
9. Butterfield DA, Kanski J (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Age Dev 122: 945-962
10. Cacabelos R, Takeda M, Winblad B (1999) The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 14: 3-47
11. Caputo CB, Salama AI (1989) The amyloid proteins of Alzheimer's disease as potential targets for drug therapy. Neurobiol Aging 10: 451-461
12. Collinge J (2001) Priori diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24: 519-550
13. Coughlan CM, Breen KC (2000) Factors influencing the processing and function of the amyloid β precursor protein - a potential therapeutic target in Alzheimer's disease? Pharmacol Ther 86: 111-144
14. Cross DAE, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77: 94-102
15. Culbert AA, Brown MJ, Frame S, Hagen T, Cross DAE, Bax B, Reith AD (2001) GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β-catenin stabilisation without elevation of glycogen synthase activity. Febs Lett 507: 288-294
16. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE (2001) Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22: 721-727
17. Davies P (1991) Therapy for Alzheimer's disease: choosing a target. Clin Neuropharmacol 14 [Suppl 1]: S24-S33
18. DiIorio P, Virgilio A, Giuliani P, Ballerini P, Vianale G, Middlemiss PJ, Rathbone MP, Ciccarelli R (2001) AIT-082 is neuroprotective against kainate-induced neuronal injury in rats. Exp Neurol 169: 392-399
19. Doody RS (1999) Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 45 [Suppl 1]: 23-32
20. Dovey HF, John V, Anderson JP, et al (2001) Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. 13. J Neurochem 76: 173-181
21. Dresser R (2000) Weighing the benefits of new Alzheimer's treatments. Science 289: 869
22. Dumery L, Bourdel F, Soussan Y, Fialkowsky A, Viale S, Nicolas P, Reboud-Ravaux M (2001) β-amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. Pathol Biol 49: 72-85
23. Farlow MR, Evans RM (1998) Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51 [Suppl 1]: S36-S44
24. Fassbender K, Masters C, Beyreuther K (2001) Alzheimer's disease: molecular concepts and therapeutic targets. Naturwissenschaften 88: 261-267
25. Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P, Runz H, Kühl S, Bertsch T, vonBergmannn K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 98: 5856-5861
26. Fisher A (1999) Muscarinic receptor agonists in Alzheimer's disease - more than just symptomatic treatment? CNS Drugs 12: 197-214
27. Fleischhacker WW, Buchgeher A, Schubert H (1986) Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 10: 87-93
28. Forloni G, Bertani I, Calella AM, Thaler F, Invernizzi R (2000) α-synuclein and Parkinson's disease: selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 47: 632-640
29. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 1-4
30. Gasser T (2001) Genetics of Parkinson's disease. J Neurol 248: 833-840
31. Giacobini E (1997) From molecular structure to Alzheimer therapy. Jpn J Pharm 74: 225-241
32. Giacobini E (2000) Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. Alz Dis Assoc Disord 14: S3-S10
33. Glasky AJ, Melchior CL, Pirzadeh B, Heydari N, Ritzmann RF (1994) Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacol Biochem Behav 47: 325-329
34. Goedert M (2001) A-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2: 492-501
35. Golde TE, Eckman CB (2001) Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. DDT 6: 3-9
36. Grundman M, Corey-Bloom J, Thal LJ (1998) Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J Neural Transm [Suppl] 53: 255-275
37. Grutzendler J, Morris JC (2001) Cholinesterase inhibitors for Alzheimer's disease. Drugs 61: 41-52
38. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases - therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716
39. Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10: 378-384
40. Harkany T, Hortobagyi T, Sasvari M, Konya C, Penke B, Luiten PGM, Nyakas C (1999) Neuroprotective approaches in experimental models of β-amyloid neurotoxicity: Relevance to Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 23: 963-1008
41. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E (2001) β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32: 213-223
42. Hefti F (1999) Nerve growth factor treatment for Alzheimer's disease: the experience of the first attempt at intracerebral neurotrophic factor therapy. In: Hefti F (ed) Neurotrophic factors. Springer, Berlin Heidelberg New York Tokyo, pp 175-187
43. Hefti F, Will B (1987) Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; implications for alzheimer's disease. J Neural Transm 24: 309-315
44. Hock C, Heese K, Müller-Spahn F, Hulette C, Rosenberg C, Otten U (1998) Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett 241: 151-154
45. Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin imbalances in Alzheimer disease decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57: 846-851
46. Hof PR, Morrison JH (1999) The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry RD, Katzman R, Bick KL, Sisodia SS (eds) Alzheimer disease, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 207-232
47. Hutter-Paier B, Frühwirth M, Windisch M (1996) Ischemia induced loss of MAP2 is prevented by Cerebrolysin and THA. Mol Biol Cell 7: 1278
48. Hutter-Paier B, Grygar E, Windisch M (1996) Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin. J Neural Transm 47: 267-273
49. Hutter-Paier B, Grygar E, Frühwirth M, Temmel I, Windisch M (1998) Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm [Suppl] 53: 363-372
50. Imbimbo BP (2001) Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 15: 375-390
51. Ingram DK (2001) Vaccine development for Alzheimer's disease: a shot of good news. Trends Neurosci 24: 305-307
52. Iqbal K, Alonso AD, Gondal JA, Gong CX, Haque N, Khatoon S, Sengupta A, Wang JZ, Grundke-Iqbal I (2000) Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm [Suppl] 59: 213-222
53. Iwai A, Yoshimoto M, Masliah E, Saitoh T (1995) Non-A β component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34: 10139-10145
54. Jain KK (2000) Evaluation of memantine for neuroprotection in dementia. Expert Opin Invest Drugs 9: 1397-1406
55. Jönhagen ME (2000) Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord 14: S31-S38
56. Jönhagen ME, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger A, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9: 246-257
57. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K (2001) Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276: 24985-24990
58. Kasa P, Rakonczay Z, Gulya K (1997) The cholinergic system in Alzheimer's disease. Prog Neurobiol 52: 511-535
59. Kotzbauer PT, Trojanowski JQ, Lee VMY (2001) Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17: 225-232
60. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH (2000) Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol Scand 102: 60-67
61. Lapchak A (1993) Nerve growth factor pharmacology: application to the treatment of cholinergic neurodegernation in Alzheimer's disease. Exp Neurol 124: 16-20
62. Lichenstein HS, Lyons DE, Wurfel MM, Johnson DA, McGinley MD, Leidli JC, Trollinger DB, Mayer JP, Wright SD, Zukowski MM (1994) Afamin is a new member of the albumin, α-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem 269: 18149-18154
63. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153: 1365-1370
64. Lippa CF, Schmidt ML, Lee VMY, Trojanowski JQ (2001) α-Synuclein in familial Alzheimer disease - epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol 58: 1817-1820
65. Malchiodi-Albedi F, Petrucci TC, Picconi B, Iosi F, Falchi M (1997) Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons. J Neurosci Res 48: 425-438
66. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W (1999) Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 62: 239-245
67. McMurray CT (2001) Huntington's disease: new hope for therapeutics. Trends Neurosci 24: S32-S38
68. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ (2001a) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(sw) mice. J Neuropathol Exp Neurol 60: 778-785
69. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ (2001b) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(sw) mice. J Neuropathol Exp Neurol 60: 778-785
70. Mukaetova-Ladinska EB, Hurt J, Jakes R, Xuereb J, Honer WG, Wischik CM (2000) α-synuclein inclusions in Alzheimer and Lewy body diseases. J Neuropathol Exp Neurol 59: 408-417
71. Nabeshima T, Yamada K (2000) Neurotrophic factor strategies for the treatment of Alzheimer disease. Alz Dis Assoc Disord 14: S39-S46
72. Newhouse PA, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer's disease. Biol Psychiat 49: 268-278
73. Nordberg A (1999) PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol 155: 4S53-4S63
74. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152: 871-877
75. Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38: 735-767
76. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
77. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces B-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899
78. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E (2001) Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 914: 48-56
79. Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, Ritter R, Schmidt R, Taneri Z, Winterer W, Koper D, Kasper S, Rainer M, Moessler H (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 16: 253-263
80. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27: 32-40
81. Rüther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M (2000) Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm 107: 815-829
82. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, A-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222
83. Satou T, Itoh T, Ohde H, Anderson AJ, Hashimoto S (2000) Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. J Neural Transm 107: 1253-1262
84. Schenk DB, Seubert P, Lieberburg I, Wallace J (2000) β-peptide immunization - a possible new treatment for Alzheimer disease. Arch Neurol 57: 934-936
85. Scott LJ, Goa KL (2000) Galantamine - a review of its use in Alzheimer's disease. Drugs 60: 1095-1122
86. Selkoe DJ (2001a) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766
87. Selkoe DJ (2001b) Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 98: 11039-11041
88. Simons M, Keller P, Dichgans J, Schulz JB (2001) Cholesterol and Alzheimer's disease - is there a link? Neurology 57: 1089-1093
89. Sirviö J (1999) Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients. Gerontology 45 [Suppl 1]: 3-14
90. Soto C, Saborio GP, Permanne B (2000) Inhibiting the conversion of soluble amyloid-β peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Acta Neurol Scand 102: 90-95
91. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E (1998) Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol 152: 367-372
92. Takenouchi T, Hashimoto M, Hsu LJ, Mackowski B, Rockenstein E, Mallory M, Masliah E (2001) Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human α-synuclein. Mol Cell Neurosci 17: 141-150
93. Taylor EM, Yan RZ, Hauptmann N, Maher TJ, Djahandideh D, Glasky AJ (2000) AIT-082, a cognitive enhancer, is transported into brain by a nonsaturable influx mechanism and out of brain by a saturable efflux mechanism. J Pharmacol Exp Ther 293: 813-821
94. Terry RD (2000) Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 59: 1118-1119
95. Terry RD, Masliah E, Hansen LA (1999) The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Terry RD, Katzman R, Bick KL, Sisodia SS (eds) Alzheimer disease, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 187-206
96. Valouskova V, Francis-Turner L, Gschanes A, Mokry J, Palecek J (1997) Long-term changes after the fimbria-fornix lesion followed by b-FGF, NGF and Cerebrolysin treatment. Soc Neurosci 23: 1447
97. Vassar R (2001) The β-secretase, BACE - a prime drug target for Alzheimer's disease. J Mol Neurosci 17: 157-170
98. Waggie KS, Kahle PJ, Tolwani RJ (1999) Neurons and mechanisms of neuronal death in neurodegenerative diseases: a brief review. Lab Anim Sci 49: 358-362
99. Wanker EE (2000) Protein aggregation in Huntington's and Parkinson's disease: implications for therapy. Mol Med Today 6: 387-391
100. Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14: 135-146
101. Xiao S, Yan H, Yao P (2000) Efficacy of FPF 1070 (Cerebrolysin) in patients with Alzheimer's disease. Clin Drug Invest 19: 43-53
102. Zhang LL, Song LX, Terracina G, Liu YH, Pramanik B, Parker E (2001) Biochemical characterization of the β-secretase activity that produces β-amyloid peptides. Biochemistry USA 40: 5049-5055